High-Dose antifungal shows promise against rare, deadly mold
NCT ID NCT00467883
First seen Mar 07, 2026 · Last updated Jun 12, 2026 · Updated 17 times
Summary
This study tested a high dose (10 mg/kg/day) of the antifungal drug liposomal amphotericin B (Ambisome) in 40 people with zygomycosis, a rare but serious fungal infection. The goal was to see if this dose could control the infection, measured by complete or partial response after 4 weeks of treatment. Researchers also looked at how well patients tolerated the drug and their survival after 15 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZYGOMYCOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker - Service des Maladies Infectieuses et Tropicales
Paris, 75015, France
-
Necker Hospital
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.